Actually, looking at those Sprott numbers again, they are valuing a Bullzeye share much higher than I said above.
Sprott suggest a Bullzeye NPV of $699M.
As I recall, prior to the two rounds of entitlement, there were approx 440M Bullzeye shares in issue. Each entitlement round was 5%, so that would make very roughly 500M Bullzeye shares in issue now... there or there abouts.
$699M/500M gets a value of $1.40 for each Bullzeye share. That's consistent with the 83c Sprott assigns to EMR SP, given they own 60% of bullzeye
So on those (which are IMO highly fanciful figures), since the script offer in Dec 2021, a Bullzeye share has risen by x4.5 (30c to $1.40) whilst an EMR share has risen by x1.85 ($1.05 to $1.95)
Sprott Report, page-23
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.22 |
Change
-0.060(1.40%) |
Mkt cap ! $2.772B | |||
| Open | High | Low | Value | Volume |
| $4.28 | $4.28 | $4.18 | $5.288M | 1.253M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5703 | $4.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.24 | 5473 | 2 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| EMR (ASX) Chart |